New drug interaction study could shape future obesity treatments

NCT ID NCT07710729

Not yet recruiting Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates whether an experimental drug called UBT251 changes how the body processes oral contraceptives and how quickly the stomach empties. It involves women who cannot become pregnant and have overweight or obesity. The goal is to understand if UBT251 can be safely taken with common medications like birth control pills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UBT251, an experimental drug, given alongside an oral contraceptive and acetaminophen
What this could lead to: If successful, this study could help determine whether UBT251 is safe to use with oral contraceptives, supporting its development as a potential treatment for overweight or obesity.
What could go wrong: This is an early-phase study with only 40 participants, so results may not apply to the broader population. The study focuses on drug interactions, not on weight loss or long-term safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Altasciences Clinical Company, Inc

Montreal, Quebec, H3P 3P1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.